Article

CMS expands coverage for OPT with verteporfin

Washington, DC-The Centers for Medicare and Medicaid Services (CMS) once again plans to expand its coverage for ocular photodynamic therapy (OPT) with verteporfin (Visudyne, Novartis Ophthalmics).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Related Content
Q&A: Michael Lai, MD, PhD, on the impact of underfunding the Good Days program
August 26th 2025

Q&A: Michael Lai, MD, PhD, on the impact of underfunding the Good Days program

Commercial real estate and your practice, part two with Colin Carr
August 26th 2025

Commercial real estate and your practice, part two with Colin Carr

Most patients support AI in health care if it means more time with doctors
August 26th 2025

Most patients support AI in health care if it means more time with doctors

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
August 26th 2025

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Pathways for better care: When patients and providers move in sync
August 26th 2025

Pathways for better care: When patients and providers move in sync

Private practice: Insights into the challenges and strategies of practice management
August 26th 2025

Private practice: Insights into the challenges and strategies of practice management

© 2025 MJH Life Sciences

All rights reserved.